STOCK TITAN

Immutep to Participate in November Investor Events

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Immutep Limited announces its management's participation in upcoming investor events in November. The events include Baird's Biotech Discovery Series and Jefferies London Healthcare Conference.
Positive
  • None.
Negative
  • None.

SYDNEY, AUSTRALIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will participate in the following upcoming investor events in November:

Baird’s Biotech Discovery Series

Details:Marc Voigt (CEO), Dr. Frederic Triebel (CSO), Christian Mueller (SVP, Regulatory & Strategy), and Dr. Wade Iams, Assistant Professor of Medicine, Director Thoracic Clinical Trials at Vanderbilt University Medical Center, will participate in a fireside chat.
Date:Thursday, 9 November 2023
Time:10:30AM ET

Jefferies London Healthcare Conference

Details:Marc Voigt (CEO) will present a corporate overview and update.
Date:Wednesday, 15 November 2023
Time:3:00PM GMT (11:00AM ET)
  

Live webcasts and replays of the fireside chat and Mr. Voigt’s presentation at the Jefferies conference will be available under the Events page within the Investors & Media section of Immutep’s website.

About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com


FAQ

What events is Immutep participating in November?

Immutep is participating in Baird's Biotech Discovery Series and Jefferies London Healthcare Conference.

Who will be participating in the fireside chat at Baird's Biotech Discovery Series?

Marc Voigt (CEO), Dr. Frederic Triebel (CSO), Christian Mueller (SVP, Regulatory & Strategy), and Dr. Wade Iams, Assistant Professor of Medicine, Director Thoracic Clinical Trials at Vanderbilt University Medical Center.

Who will be presenting at Jefferies London Healthcare Conference?

Marc Voigt (CEO) will present a corporate overview and update.

Where can I access the webcasts and replays of the events?

You can access the webcasts and replays on the Events page within the Investors & Media section of Immutep's website.

Immutep Limited American Depositary Shares

NASDAQ:IMMP

IMMP Rankings

IMMP Latest News

IMMP Stock Data

335.25M
1.06B
0.01%
2.77%
1.06%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Sydney

About IMMP

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.